The announcement of a collaboration with Genialis is a positive development for Tempus AI, as it could lead to advancements in cancer treatment. However, the immediate market reaction was negative, as evidenced by the stock price drop. This suggests that investors may have had higher expectations or concerns about the collaboration's impact on financials.